|
|
Volumn 94, Issue 22, 2002, Pages 1668-
|
|
Demand grows for early access to promising cancer drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZACITIDINE;
ANTINEOPLASTIC AGENT;
ANTIRETROVIRUS AGENT;
AZACITIDINE;
GEFITINIB;
IMATINIB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ACUTE GRANULOCYTIC LEUKEMIA;
CANCER RESEARCH;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG SAFETY;
DRUG UTILIZATION;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE POLICY;
HEALTH PROGRAM;
HUMAN;
LUNG NON SMALL CELL CANCER;
NOTE;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SIDE EFFECT;
|
|
EID: 0037146340
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.22.1668 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|